The role of dosimetry and biological effects in metastatic castration –resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study

223Ra is currently used for treatment of metastatic castration resistant prostate cancer patients (mCRPC) bone metastases with fixed standard activity. Individualized treatments, based on adsorbed dose (AD) in ta...

Source: Journal of Experimental and Clinical Cancer Research - September 6, 2021 Category: Cancer & Oncology Authors: Rosa Sciuto, Sandra Rea, Sara Ungania, Antonella Testa, Valentina Dini, Maria Antonella Tabocchini, Clarice Patrono, Antonella Soriani, Valentina Palma, Raffaella Marconi and Lidia Strigari Tags: Research Source Type: research